MBRX News and Press, Moleculin Biotech Inc.

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 2.3% to $1.75 on volume of 540,803,661 shares Interactive Strength Inc. (TRNR) rose 4.8% to $0.4287 on volume of 306,666,776 shares Theriva Biologics, Inc. (TOVX) rose 2.4% to $0.1...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.4% to $1.7852 on volume of 510,359,702 shares Interactive Strength Inc. (TRNR) rose 19.3% to $0.488 on volume of 290,201,967 shares Theriva Biologics, Inc. (TOVX) rose 9.1% to $0...

2026-02-19 08:54:28 ET More on Moleculin Biotech Moleculin announces exercise of warrants for $6.8M Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotech R...

HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants t...

Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failures First 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter; treated 35 subjects to date with anot...

HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent Application No. 2021-577862 titled, “METHOD OF RECO...

CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos Access the Moleculin CEO Corner h...

–  Live video webcast on Wednesday, February 11 th at 1:20 PM EST    HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will participate in the ...

– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multiple oncology indications HOUSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Molecul...

– First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or...